Vimta Labs growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+18.4%	+8.9%
EBITDA	+16.1%	+14.8%
Net Income	+15.1%	+17.9%
EPS (adj.)	+15.1%	+17.9%
Total Assets	+20.5%	+16.0%
Total Equity	+20.6%	+17.6%
Free Cash Flow	+213.4%	+8.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

VIMTALABS₹519.80

Vimta Labs Limited

· Pharma & Health

₹ CrorePeersSUVEN TAKEMcap ₹2,322 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+18.4	+8.9
EBITDA	+16.1	+14.8
Net Income	+15.1	+17.9
EPS (adj.)	+15.1	+17.9
Total Assets	+20.5	+16.0
Total Equity	+20.6	+17.6
Free Cash Flow	+213.4	+8.8

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.